Le Lézard
Classified in: Health, Science and technology
Subject: SVY

Global Host Cell Contaminant Testing Market to Reach US$ 354 Mn by 2025 - Persistence Market Research


NEW YORK, February 19, 2018 /PRNewswire/ --

- The global market is expected to be led by bio-pharmaceutical companies

- It accounted for a share of 51.4% of the global host cell contaminant testing market in 2017 and is expected to maintain a dominant position in the market over the course of the forecast period

Persistence Market Research (PMR) has recently published a report titled "Host Cell Contaminant Testing Market: Global Industry Analysis (2012 - 2016) and Forecast (2017 - 2025)." The report states that the healthcare industry is transforming at a rapid pace and is venturing into different possibilities for research and development of new technologies. Several government and regulatory bodies of various countries are adopting various cost containment measures to reduce healthcare burden, especially in developed economies. This shift from volume- to value based system is driven by various measures taken by governments, providers, payers and life sciences companies, which include outcome-based pricing, profit and risk sharing, price control and competitive tendering. The value-based healthcare system will help in achieving maximum value for the money spent on healthcare and thus, improve the outcomes through integrated care pathways, but at the same time will levy pricing pressure on the biopharmaceutical companies and may impact the investment in R&D of innovative medical treatment technologies. The global market for host cell contaminant testing market is expected to rise at a stable CAGR of 5.6% from 2017 to 2025. The market is expected to touch a US$ 354 Mn by the end of 2025.

     (Logo: http://photos.prnewswire.com/prnh/20161114/438683LOGO )

Global Host Cell Contaminant Testing Market Research Report Overview @ https://www.persistencemarketresearch.com/market-research/host-cell-contaminant-testing-market.asp

Bio-Safety of Drugs to be Key Growth Driving Factor 

Biopharmaceutical products manufactured from biological systems may be contaminated with host cell components. Host cell contaminants constitute major parts of process-related impurities and can severely affect drug safety. Even though low levels of most of the host cell contaminants may be insignificant, but due to patient safety host cell contaminants are reduced to low levels or eliminated to reduce adverse immune reactions. Failure to identify host cell contaminants in early stages of manufacturing results in reduced drug efficacy or adverse reactions on patients. Biosafety of patient population is primary requisite, host cell contaminant testing is performed at each and every step of biopharmaceutical manufacturing to eliminate the risk of host cell contaminants.

However, the diversity of proteins which is within the host cell contaminants is expected to pose various challenges in the testing of contaminants in the coming years. Dearth of coverage for non-immune reactive host cell contaminants and lack of identification and specificity are expected further hinder the growth of the market in the long run.

Request Sample Report@ https://www.persistencemarketresearch.com/samples/21355

North America Topping the Charts with High Adoption Rate 

Region wise, the host cell contaminant testing market is sectioned into five key regions namely Latin America, North America, Asia Pacific (APAC), Europe, and the Middle East and Africa (MEA). The North America has turned into the lucrative market for host cell contaminant testing and is expected to rise as the quickest developing business sector because of activities like estimation of biotechnology programs that help the United Kingdom's National Measurement System. Asia Pacific area is relied upon to enlist a huge development over a figure period. Europe is additionally anticipated to enlist a noteworthy development in the host cell contaminant testing market over a conjecture period.

Based on product type, ELISA based assays segment is expected to occupy a huge share in the global cell contaminant testing market. On the basis of application, the market was led by product manufacturing.

 Download and View Report TOC, Figures and Tables @ https://www.persistencemarketresearch.com/market-research/host-cell-contaminant-testing-market/toc

Vendors to Focus on Structured Research and Development 

The companies operating in the market are Cisbio Bioassays, Cygnus Technologies LLC (A Maravai Lifesciences Company), Bio-Rad Laboratories, Inc., Enzo Life Sciences, Inc., BioGenes GmbH, ForteBio (A Pall Company), Molecular Devices LLC, GE Healthcare Life Sciences, Thermo Fisher Scientific, Inc., and ProteinSimple (a Biotech Brand), among others. These companies are highly focusing on research and development.

Get full Report Now @ https://www.persistencemarketresearch.com/checkout/21355

Persistence Market Research Overview 

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact
Persistence Market Research
U.S. Sales Office:
305 Broadway, 7th Floor
New York City, NY 10007
+1-646-568-7751
United States
USA - Canada Toll-Free: 800-961-0353
Email: [email protected]

PMR Latest News: https://www.persistencemarketresearch.com/news



These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIOŽ (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: